Day Two

• Optimizing physical chemical properties for more favourable ADME characteristics of TACs
• Leveraging PROTACs as binders for antibodies, as well as payloads
• Discussing rationally designing candidates that break out of the structural constraints of E3 ligases

Present your company’s slides by securing a 15 minute presentation slot in front of the attending audience.

What is this session?

Following the same structure as the two presentation sessions on conference day one, these are further presentation slots, so pharma and investors have more opportunity to listen to pitches from leading biotech across Asia.

Whether you are seeking to increase interest specifically with big pharma, or didn’t manage enough exposure at JPM or BIO conferences, this is a more targeted opportunity to share your company profile with key buyers.

• For both venture and investing out of public funds, what will drive investment in targeted therapies and what will inhibit it?
• How has the impact of the barrier for entry of next generation innovations lowering fed through into investment?
• How to progress discussions with investors. What is expected and

What is this session?

Following the investor panel where the audience will understand investor interests, this formal networking ensures each biotech can introduce yourself to each investor

How will this session run?

Join high tables in small groups with an investor at each table. For rounds of five minutes, biotech stays at tables and investors move around. Rapidly gauge alignment between portfolios and stage of the company, share business cards, or ask a follow-up question from the panel before the investors rotate and a new round begins.

• Reviewing differences in bispecific modalities including dual inhibitors, agonists, T-cell and other immune-cell engagers
• How are novel targets and formats expanding engager pipelines across both blood and solid tumors?
• What does this mean for the potential first-in-class engager approvals?
• How can engagers and bispecifics be complementary to other drug modalities to improve patient outcomes?

• How can we improve toxicity profiles and delivery better than Enhertu?
• What and how are leaders achieving efficacy beyond a monospecific with a BsAb and BsADCs
• Leveraging synergy between biology of targets and binding events to improve ADC performance

• Discussing different pharmacokinetic properties of binders, including small molecule, peptide, mAbs and nanoparticles
• Evaluating need, niche, and efficacy when matching target biology to binder format and isotope
• Leveraging imaging to derisk and prove safety to curate a faster path to clinical proof of concept
• How do considerations around isotopes play into deal-making?

Present your company’s slides by securing a 15 minute presentation slot in front of the attending audience.

What is this session?

So as to host as many exciting pipeline updates and introductions to exciting new companies as possible, this is an additional session with presentation sessions available to those attending. Make sure you don’t leave the conference without getting to pitch your technologies for out-licensing or co-development to those with decision-making power, prioritizing access to Asia assets.